Literature DB >> 10529362

Immunosuppressive effect of leukotriene B(4) receptor antagonist in vitro.

H Morita1, K Takeda, H Yagita, K Okumura.   

Abstract

Leukotriene B(4) (LTB(4)), which is an arachidonic acid metabolite produced by the 5-lipoxygenase pathway and a well-characterized chemical mediator of inflammation, has been proposed to be an immune response modulator. Here we showed the constitutive expression of the LTB(4) receptor (LTB(4)R) in resting and activated T cells. We found that the LTB(4)R antagonist inhibited T cell proliferation induced by Con A, immobilized anti-CD3 mAb, or IL-2. This inhibitory effect was abolished by addition of LTB(4)R agonist. The LTB(4)R antagonist inhibited IL-2, IFN-gamma, and IL-4 production by anti-CD3-stimulated T cells and also inhibited IL-12-induced IFN-gamma production. Moreover, the LTB(4)R antagonist exerted an additive inhibitory effect to FK506 on T cell proliferation. These results suggest that LTB(4) is intrinsically involved in T cell activation to upregulate cytokine production and proliferation, and thus the LTB(4)R antagonist might be useful as an immunosuppressive agent. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10529362     DOI: 10.1006/bbrc.1999.1523

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  The release of leukotriene B4 from human skin in response to substance P: evidence for the functional heterogeneity of human skin mast cells among individuals.

Authors:  T Okabe; M Hide; O Koro; N Nimi; S Yamamoto
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

2.  The combined effects of zafirlukast, prednisone, and inhaled budesonide on IL-13 and IFN-gamma secretion.

Authors:  Fiona K Gibbons; Elliot Israel; Aaron Deykin; Bianca Schaub; Hong Z He; David L Perkins; Patricia W Finn
Journal:  J Clin Immunol       Date:  2005-09       Impact factor: 8.317

3.  Leukotrienes modulate cytokine release from dendritic cells.

Authors:  Szczepan Jozefowski; Rafał Biedroń; Malgorzata Bobek; Janusz Marcinkiewicz
Journal:  Immunology       Date:  2005-12       Impact factor: 7.397

4.  Blockade of endogenous leukotrienes exacerbates pulmonary histoplasmosis.

Authors:  Alexandra I Medeiros; Anderson Sá-Nunes; Edson G Soares; Camila M Peres; Célio L Silva; Lúcia H Faccioli
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

5.  Expression of 5-lipoxygenase (5-LOX) in T lymphocytes.

Authors:  Jeanne M Cook-Moreau; Yola El-Makhour Hojeij; Guislaine Barrière; Hélène C Rabinovitch-Chable; Karine S Faucher; Franck G Sturtz; Michel A Rigaud
Journal:  Immunology       Date:  2007-05-02       Impact factor: 7.397

6.  A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders.

Authors:  T Yokomizo; K Kato; K Terawaki; T Izumi; T Shimizu
Journal:  J Exp Med       Date:  2000-08-07       Impact factor: 14.307

7.  Proinflammatory and immunoregulatory roles of eicosanoids in T cells.

Authors:  Anna Mari Lone; Kjetil Taskén
Journal:  Front Immunol       Date:  2013-06-04       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.